Get the Stockscreener App
179.89
1.22%
2.16
After Hours:
179.89
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $179.89, with a volume of 73,570.
It is up +1.22% in the last 24 hours and up +8.53% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$177.73
Open:
$178.68
24h Volume:
73,570
Relative Volume:
0.31
Market Cap:
$3.53B
Revenue:
$152.42M
Net Income/Loss:
$45.24M
P/E Ratio:
71.67
EPS:
2.51
Net Cash Flow:
$6.97M
1W Performance:
-1.49%
1M Performance:
+8.53%
6M Performance:
+72.52%
1Y Performance:
+74.75%
1-Day Range:
$177.85
$181.35
1-Week Range:
$177.35
$186.40
52-Week Range:
$93.58
$186.40
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
179.89 | 3.46B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Stifel | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Price action breakdown for Ligand Pharmaceuticals IncorporatedVolume Spike & Daily Growth Stock Tips - newser.com
Can Ligand Pharmaceuticals Incorporated stock sustain market leadershipDividend Hike & Reliable Trade Execution Plans - newser.com
Combining price and volume data for Ligand Pharmaceuticals IncorporatedLayoff News & Stock Timing and Entry Methods - newser.com
Real time alert setup for Ligand Pharmaceuticals Incorporated performanceWall Street Watch & Real-Time Chart Breakout Alerts - newser.com
Analyzing drawdowns of Ligand Pharmaceuticals Incorporated with statistical toolsTrade Risk Summary & Fast Moving Stock Watchlists - newser.com
Can Ligand Pharmaceuticals Incorporated stock deliver sustainable ROEEarnings Beat & Technical Pattern Alert System - newser.com
Trend analysis for Ligand Pharmaceuticals Incorporated this weekTrade Ideas & High Accuracy Swing Entry Alerts - newser.com
Is Ligand Pharmaceuticals Incorporated forming a reversal patternWatch List & Daily Stock Trend Watchlist - newser.com
Published on: 2025-10-12 10:25:04 - newser.com
Ligand Pharmaceuticals (LGND): Evaluating Valuation After FDA Green Light for Lasix ONYU’s At-Home Heart Failure Solution - simplywall.st
Villere ST Denis J & Co. LLC Has $32.64 Million Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals (NASDAQ:LGND) Earns Sell (D+) Rating from Weiss Ratings - MarketBeat
Order flow analysis tools used on Ligand Pharmaceuticals IncorporatedPortfolio Performance Report & Consistent Profit Focused Trading Strategies - newser.com
How FDA Approval of Lasix ONYU Expands Ligand Pharmaceuticals' (LGND) Royalty Pipeline and Revenue Potential - simplywall.st
Ligand Pharmaceuticals Hits New 52-Week High of $186.40 - Markets Mojo
Ligand Partner SQ Innovation Gets FDA Approval for At-Home Edema Treatment for Heart Failure Patients - MarketScreener
Ligand (LGND) Gains FDA Approval for Lasix ONYU, Enhancing Heart Failure Treatment - GuruFocus
Ligand Pharmaceuticals Announces FDA Approval of Lasix ONYU, Innovative Subcutaneous Delivery Device for Edema Treatment in Heart Failure Patients - Quiver Quantitative
Ligand Pharmaceuticals Reaches Analyst Target Price - Nasdaq
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients - GlobeNewswire Inc.
Is Ligand Pharmaceuticals Incorporated (LGDN) stock bottoming after sell off2025 Momentum Check & Reliable Intraday Trade Plans - newser.com
Risk adjusted return profile for Ligand Pharmaceuticals Incorporated analyzedGlobal Markets & Short-Term High Return Ideas - newser.com
Ligand Pharmaceuticals Hits New 52-Week High of $184.26 - Markets Mojo
Ligand Pharmaceuticals Hits New 52-Week High of $183.81 - Markets Mojo
What analysts say about Ligand Pharmaceuticals Incorporated LGDN stockStock Rotation Strategies & Access Insider-Level Stock Analysis - earlytimes.in
Ligand Pharmaceuticals (NASDAQ:LGND) Reaches New 1-Year HighHere's What Happened - MarketBeat
Ligand Pharmaceuticals stock hits 52-week high at $183.98 By Investing.com - Investing.com Canada
Hot Picks: Three mid-cap stock picks poised for growth amid strong sector tailwinds - BNN Bloomberg
How to read the order book for Ligand Pharmaceuticals IncorporatedEarnings Miss & Real-Time Volume Trigger Notifications - newser.com
Ligand Pharmaceuticals Hits New 52-Week High of $181.62 - Markets Mojo
Press Release: Ligand Reports First Quarter 2025 Financial Results - 富途牛牛
Insider Sell Alert: John Kozarich Sells Shares of Ligand Pharmac - GuruFocus
Ligand Pharmaceuticals (NASDAQ:LGND) Director John Kozarich Sells 467 Shares - MarketBeat
Ligand Pharmaceuticals Hits New 52-Week High at $177.77 - Markets Mojo
Ligand Pharmaceuticals IncorporatedEquity Right (LGNYZ) Price Target Increased by 410.53% to 0.05 - Nasdaq
Ligand Pharmaceuticals stock hits 52-week high at $172.49 By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (NASDAQ:LGND) Reaches New 12-Month HighWhat's Next? - MarketBeat
What drives Ligand Pharmaceuticals Incorporated LGDN stock priceBollinger Bands Signals & Affordable Stock Market Tips - earlytimes.in
What drives Ligand Pharmaceuticals Incorporated stock priceHead and Shoulders Patterns & Small Budget Capital Gains - Early Times
Ligand Pharmaceuticals Hits New 52-Week High of $170.78 - Markets Mojo
Ligand Pharmaceuticals Hits New 52-Week High of $172.45 - Markets Mojo
Congress Asset Management Co. Raises Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals director Aryeh sells $1.7 million in shares By Investing.com - Investing.com Australia
LGND: Ligand Pharmaceuticals Inks $11M Royalty Deal with Arecor - GuruFocus
Arecor Therapeutics announces royalty financing agreement with Ligand to raise up to $11 mln - MarketScreener
Ligand Pharmaceuticals director Aryeh sells $1.7 million in shares - Investing.com
Ligand Pharmaceuticals (NASDAQ:LGND) Hits New 12-Month HighTime to Buy? - MarketBeat
Contravisory Investment Management Inc. Acquires New Holdings in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Analysts Set Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) PT at $176.50 - MarketBeat
Strs Ohio Takes Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):